Charter Communications Agrees To $25M Settlement With SEC For Stock Buyback Violations

The Securities and Exchange Commission announced settling charges against Charter Communications Inc.

The Securities and Exchange Commission announced settling charges against Charter Communications Inc. (NASDAQ:CHTR) for breaches in stock buyback accounting controls.

Although Charter’s board allowed buybacks under SEC Rule 10b5-1, which guards against insider trading if certain conditions are met, from 2017 to 2021, Charter deviated from these rules. 

They employed “accordion” provisions in their plans, granting flexibility to alter buyback amounts and timing. 

This practice, employed in nine different plans over four years, didn’t comply with Rule 10b5-1’s stipulations, leading to buybacks that weren’t in line with board approvals. 

The SEC concluded that Charter’s non-compliance with Rule 10b5-1, evident in their repeated misaligned trading plans, stemmed from inadequate internal accounting controls.

Also Read: Charter Communications Residential Video Subscribers Are Falling, Stock Slides

Charter breached Section 13(b)(2)(B) of the Exchange Act, agreeing to a cease-and-desist order and a $25 million fine without admitting or denying the findings.

In a statement, Charter affirmed its full cooperation with the SEC investigation and stated its share buyback plans were thoroughly documented and disclosed. 

The company reiterated its commitment to its share repurchase program and existing leverage goals, as reported by Reuters.

Price Action: CHTR shares are trading lower by 2.03% at $406.41 premarket on the last check Wednesday.

Disclaimer: This content was partially produced with the help of AI tools and was Reviewed And Published By Benzinga Editors.

Total
0
Shares
Related Posts
Read More

FDA Approves AstraZeneca Treatment For Advanced Endometrial Cancer

AstraZeneca's breakthrough drug, Imfinzi, combined with chemotherapy, has been officially approved by the FDA to treat advanced forms of endometrial cancer with mismatch repair deficiency. This critical approval is based on Phase III trial results showing a 58% reduction in disease progression, promising improved outcomes for those battling this severe cancer.

AZN